<DOC>
	<DOCNO>NCT03086278</DOCNO>
	<brief_summary>AST-008 dose subcutaneously healthy volunteer combine SAD/MAD study evaluate safety , tolerability , pharmacokinetics pharmacodynamics .</brief_summary>
	<brief_title>A Phase 1 Study AST 008 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Main 1 . Healthy male female subject age ≥18 ≤40 year age time first dosing . 2 . Subjects must body mass index ( BMI ) 18.025.0 kg/m² inclusive . 3 . Satisfactory medical assessment clinically significant relevant abnormality determine medical history , physical examination , vital sign , 12lead ECG , clinical laboratory evaluation ( haematology , biochemistry , coagulation , urinalysis ) reasonably likely interfere subject 's participation ability complete study assess Investigator . 4 . Ability provide write , personally sign , date informed consent participate study , accordance ICH Good Clinical Practice ( GCP ) Guideline E6 ( 1996 ) applicable regulation , complete studyrelated procedure . 5 . An understanding , ability , willingness fully comply study procedure restriction . Main 1 . Current recurrent disease ( e.g. , cardiovascular , haematological , neurological , endocrine , renal , liver , GI condition ) could affect action , absorption , disposition AST008 , could affect clinical assessment clinical laboratory evaluation . 2 . Any history cancer . 3 . Any history ( include significant confirm family history ) autoimmune antibodymediated disease include limited : systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , autoimmune hepatitis , thrombocytopenia . 4 . Has acute illness within two week prior screen . 5 . Current relevant history physical psychiatric illness may require treatment make subject unlikely fully comply requirement study complete study , condition present undue risk investigational product study procedure . 6 . Any significant disease disorder , opinion investigator , may either put subject risk participation study may influence result study , subject 's ability participate study . 7 . Female subject pregnant breastfeeding . 8 . Subjects abnormal finding inguinal , axillary , cervical lymph node screen Day 1 . 9 . A positive human immunodeficiency virus ( HIV ) antibody screen , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody screen . 10 . Titres reference range ( accord local laboratory ) autoimmune antibody : rheumatoid factor ( RF ) , antinuclear antibody ( ANA ) , antineutrophil cytoplasmic antibody ( ANCA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>